Skip to main content

Aclaris Therapeutics, Inc.

corporate_fare Company Profile

Aclaris Therapeutics, Inc.

ACRS·NASDAQ·Life Sciences·CIK 0001557746

We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. Our proprietary KINect drug discovery platform, combined with our integrated discovery approach for small and large molecules, allows us to identify and advance product candidates designed for superior target affinity, specificity, and potency. We aim to identify and complete transactions with third-party partners to further develop, obtain marketing approval for, and/or commercialize our novel product candidates. We are dedicated to developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. Our approach includes leveraging our discovery, research, and development expertise, which encompasses state-of-the-art capabilities in small molecule and antibody development, including cell and molecular biology, biochemistry, enzymology, biomarker development, immunology, translational research, in vivo efficacy models, structure-based drug design ("SBDD"), and bioanalytical, computational, and medicinal chemistry. Our team also has broad experience in clinical development and strategy across atopic, respiratory, inflammatory, and immunologic diseases. We also develop innovative biologic product candidates targeting validated pathways, advancing biologics programs comprising monoclonal and multispecific antibodies targeting well-characterized pathways in immuno-inflammatory diseases. Our biologics pipeline includes bosakitug (ATI-045), an anti-thymic stromal lymphopoietin ("TSLP") monoclonal antibody, which has unique differentiation demonstrated by its low dissociation rate, long residence time, and high potency. TSLP is a master regulator of type 2 ("Th2") immune responses and a broadly active key mediator in various inflammatory conditions.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ACRS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Aclaris Therapeutics Reports Q4/FY2025 Results, Extends Cash Runway to H2 2028, Advances Multiple Pipeline Programs
  • Aclaris Therapeutics Unveils Strong Clinical Pipeline Progress and Extended Cash Runway
  • Aclaris Therapeutics Reports Positive Phase 1a Results for ATI-052, Advancing to Phase 1b/2b Trials

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$7.83M
Net Income
-$64.92M
Diluted EPS
-$0.53
Op. Cash Flow
-$47.11M
Free Cash Flow
-$47.22M
Gross Profit
$5.74M
Operating Income
-$76.38M
Cash & Equivalents
$19.96M
Debt / Equity
0.00×
Net Margin
-8.30×
Shares Outstanding
120.5M sh
Source: 10-K · filed 2026-02-26 · accession 0001104659-26-020540
$3.44
52-week range · as of 2026-11-16 $2.25 – $6.6
Market cap
$545.63M
Volume
2.2M (0.8× avg)
3-mo avg 2.8M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ACRS - Filings & News (Page 2)

ACRS
Feb 26, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.23
Real-time Price: $3.44 info
Change: +$0.210 (+7%) info
Market Cap: $545.626M info
ACRS
Jan 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.64
Real-time Price: $3.44 info
Change: +$0.800 (+30%) info
Market Cap: $545.626M info
ACRS
Jan 06, 2026, 7:16 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.78
Real-time Price: $3.44 info
Change: +$0.660 (+24%) info
Market Cap: $545.626M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets